166 related articles for article (PubMed ID: 20346875)
1. In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass.
Eriksson O; Jahan M; Johnström P; Korsgren O; Sundin A; Halldin C; Johansson L
Nucl Med Biol; 2010 Apr; 37(3):357-63. PubMed ID: 20346875
[TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus.
Kung MP; Hou C; Lieberman BP; Oya S; Ponde DE; Blankemeyer E; Skovronsky D; Kilbourn MR; Kung HF
J Nucl Med; 2008 Jul; 49(7):1171-6. PubMed ID: 18552132
[TBL] [Abstract][Full Text] [Related]
3. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
[TBL] [Abstract][Full Text] [Related]
4. In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.
Normandin MD; Petersen KF; Ding YS; Lin SF; Naik S; Fowles K; Skovronsky DM; Herold KC; McCarthy TJ; Calle RA; Carson RE; Treadway JL; Cline GW
J Nucl Med; 2012 Jun; 53(6):908-16. PubMed ID: 22573821
[TBL] [Abstract][Full Text] [Related]
5. Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas.
Fagerholm V; Mikkola KK; Ishizu T; Arponen E; Kauhanen S; Någren K; Solin O; Nuutila P; Haaparanta M
J Nucl Med; 2010 Sep; 51(9):1439-46. PubMed ID: 20720057
[TBL] [Abstract][Full Text] [Related]
6. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
[TBL] [Abstract][Full Text] [Related]
7. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats.
Tsao HH; Lin KJ; Juang JH; Skovronsky DM; Yen TC; Wey SP; Kung MP
Nucl Med Biol; 2010 May; 37(4):413-9. PubMed ID: 20447551
[TBL] [Abstract][Full Text] [Related]
8. Visualizing pancreatic beta-cell mass with [11C]DTBZ.
Simpson NR; Souza F; Witkowski P; Maffei A; Raffo A; Herron A; Kilbourn M; Jurewicz A; Herold K; Liu E; Hardy MA; Van Heertum R; Harris PE
Nucl Med Biol; 2006 Oct; 33(7):855-64. PubMed ID: 17045165
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [
Naganawa M; Lim K; Nabulsi NB; Lin SF; Labaree D; Ropchan J; Herold KC; Huang Y; Harris P; Ichise M; Cline GW; Carson RE
Mol Imaging Biol; 2018 Oct; 20(5):835-845. PubMed ID: 29468404
[TBL] [Abstract][Full Text] [Related]
10. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine.
Kung HF; Lieberman BP; Zhuang ZP; Oya S; Kung MP; Choi SR; Poessl K; Blankemeyer E; Hou C; Skovronsky D; Kilbourn M
Nucl Med Biol; 2008 Nov; 35(8):825-37. PubMed ID: 19026944
[TBL] [Abstract][Full Text] [Related]
11. Deuterated
Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
[TBL] [Abstract][Full Text] [Related]
12. Derivatization of (±) dihydrotetrabenazine for copper-64 labeling towards long-lived radiotracers for PET imaging of the vesicular monoamine transporter 2.
Kumar A; Lo ST; Öz OK; Sun X
Bioorg Med Chem Lett; 2014 Dec; 24(24):5663-5665. PubMed ID: 25467156
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.
Kilbourn MR; Hockley B; Lee L; Hou C; Goswami R; Ponde DE; Kung MP; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):233-7. PubMed ID: 17383572
[TBL] [Abstract][Full Text] [Related]
14. Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes.
Freeby MJ; Kringas P; Goland RS; Leibel RL; Maffei A; Divgi C; Ichise M; Harris PE
Mol Imaging Biol; 2016 Apr; 18(2):292-301. PubMed ID: 26370678
[TBL] [Abstract][Full Text] [Related]
15. An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [
Zhao C; Liu C; Tang J; Xu Y; Xie M; Chen Z
Mol Imaging Biol; 2020 Apr; 22(2):265-273. PubMed ID: 31165386
[TBL] [Abstract][Full Text] [Related]
16. PET Imaging of VMAT2 with the Novel Radioligand [
Nag S; Jahan M; Tóth M; Nakao R; Varrone A; Halldin C
ACS Chem Neurosci; 2021 Dec; 12(24):4580-4586. PubMed ID: 34813272
[TBL] [Abstract][Full Text] [Related]
17. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.
Koeppe RA; Frey KA; Kuhl DE; Kilbourn MR
J Cereb Blood Flow Metab; 1999 Dec; 19(12):1376-84. PubMed ID: 10598942
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of
Naganawa M; Lin SF; Lim K; Labaree D; Ropchan J; Harris P; Huang Y; Ichise M; Carson RE; Cline GW
Nucl Med Biol; 2016 Dec; 43(12):743-751. PubMed ID: 27673755
[TBL] [Abstract][Full Text] [Related]
19. Decreased defluorination using the novel beta-cell imaging agent [18F]FE-DTBZ-d4 in pigs examined by PET.
Jahan M; Eriksson O; Johnström P; Korsgren O; Sundin A; Johansson L; Halldin C
EJNMMI Res; 2011 Dec; 1(1):33. PubMed ID: 22214308
[TBL] [Abstract][Full Text] [Related]
20. VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease.
Freeby M; Goland R; Ichise M; Maffei A; Leibel R; Harris P
Diabetes Obes Metab; 2008 Nov; 10 Suppl 4():98-108. PubMed ID: 18834437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
